Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease
Sponsor: Actelion
Terminated
Slow enrollment
Other terminated trials from Actelion
- Chronic Thromboembolic Pulmonary Hypertension · Phase PHASE3 · Dec 2023
- Pulmonary Arterial Hypertension · Phase PHASE4 · Jul 2023
- Sarcoidosis-associated Pulmonary Hypertension · Phase PHASE2 · Apr 2023
- Pulmonary Arterial Hypertension · Phase PHASE4 · Dec 2022
- Chronic Thromboembolic Pulmonary Hypertension · Phase PHASE3 · Jun 2022
Other Pulmonary Hypertension trials with similar outcome
This PHASE3 trial investigates Pulmonary Hypertension and is currently terminated or withdrawn. Actelion leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Actelion
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.